Predictive and Experimental Immunogenicity of Burkholderia Collagen-like Protein 8-Derived Antigens

Megan E Grund1, Eliza Kramarska2, Soo Jeon Choi1

  • 1Department of Microbiology, Immunology and Cell Biology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA.

Vaccines
|November 27, 2021
PubMed

Insights

A new vaccine targeting Burkholderia pseudomallei, the cause of melioidosis, shows promise. Synthetic peptide formulations elicited a strong antibody response in mice, paving the way for future protection studies.

Area of Science:

  • * Infectious disease research
  • * Vaccine development
  • * Immunology

Background:

  • * Burkholderia pseudomallei causes melioidosis, a severe infection with high mortality and no current vaccine.
  • * Melioidosis affects 165,000 people annually, posing a significant clinical and biodefense challenge.

Purpose of the Study:

  • * To investigate the antigen-specific immune response to a novel vaccine candidate for B. pseudomallei.
  • * To evaluate vaccine formulations based on outer membrane protein Bucl8 components.

Main Methods:

  • * Bioinformatic tools were used to predict non-allergenic, non-toxic epitopes from Bucl8.
  • * Vaccines were formulated using extracellular Bucl8 components (β-barrel loops, collagen domains) as recombinant proteins or synthetic peptides with adjuvant.
  • * Antigen-specific immune responses were assessed in mouse sera and lymphoid organs (CD-1 and C57BL/6 models).

Main Results:

  • * Vaccination with Bucl8 components and AddaVax adjuvant induced a robust TH2-skewed antibody response, with limited TH1 response.
  • * Synthetic loop peptides resulted in a stronger, more consistent antibody response (higher IgG titers) compared to recombinant proteins.
  • * A similar TH2-skewed response was observed in the C57BL/6 mouse model using peptide-based vaccines.

Conclusions:

  • * Bucl8-derived synthetic peptide vaccines elicit a significant antigen-specific antibody response in mouse models.
  • * These findings support the further development of Bucl8-based vaccines for melioidosis protection.